Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo

被引:116
作者
Yamawaki, T
Shimokawa, H
Kozai, T
Miyata, K
Higo, T
Tanaka, E
Egashira, K
Shiraishi, T
Tamai, H
Igaki, K
机构
[1] Kyushu Univ, Sch Med, Angiocardiol Res Inst, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Sch Med, Cardiovasc Clin, Fukuoka 812, Japan
[3] Kaneka Corp, Takasago Res Labs, Res Inst, Takasago, Hyogo, Japan
[4] Shiga Med Ctr Adults, Shiga, Japan
[5] Igaki Med Planning, Kyoto, Japan
关键词
D O I
10.1016/S0735-1097(98)00312-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This study was designed to examine whether or not intramural delivery of ST638 (a specific tyrosine kinase inhibitor) with biodegradable stent can suppress the restenotic changes of the coronary artery in vivo. Background. Clinical and animal studies demonstrated that restenosis after coronary intervention results from a combined effect of neointimal formation and geometric remodeling (decrease in total cross-sectional area). Thus, the most effective strategy to prevent the restenosis appears to inhibit both the neointimal formation and geometric remodeling by antiproliferative agent and stent, respectively. We have previously shown that ST638 markedly suppresses the restenotic changes of the porcine coronary artery when applied from the adventitial site. Methods. A poly-L-lactic acid biodegradable stent was coated with either ST638 (0.8 mg) or equimolar of its inactive metabolite, ST494. A pair of these stents were implanted alternatively in the left anterior descending or circumflex coronary artery in pigs (n = 6). Three weeks after the procedure, coronary stenosis was assessed by angiography followed by histological examination. Results. Coronary stenosis was significantly less at the ST638 stent site than at the ST494 stent site (47 +/- 5% vs. 25 +/- 4%, p < 0.01), Histological examination also showed that the extent of neointimal formation and that of geometric remodeling were significantly less at the ST638 stent site than at the ST494 stent site (p < 0.05). Conclusions. These results indicate that intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent overcomes the proliferative stimuli caused by balloon injury, the stent itself, and the drug coating on the stent, resulting in the suppression of the restenotic changes of the coronary artery in vivo. This strategy might also be useful in the clinical setting in humans, (J Am Coll Cardiol 1998;32:780-6) (C)1998 by the American College of Cardiology.
引用
收藏
页码:780 / 786
页数:7
相关论文
共 36 条
[21]  
POPMA JJ, 1990, AM J MED, V88, pN1
[22]   CHEMOTACTIC ATTRACTION OF HUMAN FIBROBLASTS TO TYPE-I, TYPE-2, AND TYPE-3 COLLAGENS AND COLLAGEN-DERIVED PEPTIDES [J].
POSTLETHWAITE, AE ;
SEYER, JM ;
KANG, AH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (02) :871-875
[23]   THE PATHOGENESIS OF ATHEROSCLEROSIS - A PERSPECTIVE FOR THE 1990S [J].
ROSS, R .
NATURE, 1993, 362 (6423) :801-809
[24]   BIODEGRADABLE HOLLOW FIBERS FOR THE CONTROLLED RELEASE OF DRUGS [J].
SCHAKENRAAD, JM ;
OOSTERBAAN, JA ;
NIEUWENHUIS, P ;
MOLENAAR, I ;
OLIJSLAGER, J ;
POTMAN, W ;
EENINK, MJD ;
FEIJEN, J .
BIOMATERIALS, 1988, 9 (01) :116-120
[25]   ENZYMATIC-ACTIVITY TOWARD POLY(L-LACTIC ACID) IMPLANTS [J].
SCHAKENRAAD, JM ;
HARDONK, MJ ;
FEIJEN, J ;
MOLENAAR, I ;
NIEUWENHUIS, P .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1990, 24 (05) :529-545
[26]  
SCHEERDER ID, 1997, CIRCULATION, V95, P1549
[27]   CHEMOTACTIC RESPONSES OF FIBROBLASTS TO TROPOELASTIN AND ELASTIN-DERIVED PEPTIDES [J].
SENIOR, RM ;
GRIFFIN, GL ;
MECHAM, RP .
JOURNAL OF CLINICAL INVESTIGATION, 1982, 70 (03) :614-618
[28]   A COMPARISON OF BALLOON-EXPANDABLE-STENT IMPLANTATION WITH BALLOON ANGIOPLASTY IN PATIENTS WITH CORONARY-ARTERY DISEASE [J].
SERRUYS, PW ;
DEJAEGERE, P ;
KIEMENEIJ, F ;
MACAYA, C ;
RUTSCH, W ;
HEYNDRICKX, G ;
EMANUELSSON, H ;
MARCO, J ;
LEGRAND, V ;
MATERNE, P ;
BELARDI, J ;
SIGWART, U ;
COLOMBO, A ;
GOY, JJ ;
VANDENHEUVEL, P ;
DELCAN, J ;
MOREL, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (08) :489-495
[29]  
SHATZ RA, 1989, CIRCULATION, V79, P445
[30]   SPECIFIC INHIBITORS OF TYROSINE-SPECIFIC PROTEIN-KINASE, SYNTHETIC 4-HYDROXYCINNAMAMIDE DERIVATIVES [J].
SHIRAISHI, T ;
DOMOTO, T ;
IMAI, N ;
SHIMADA, Y ;
WATANABE, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 147 (01) :322-328